FDMT
4D Molecular Therapeutics, Inc. · Healthcare · Market cap $832.7M
Insiders sold $3.1M net in the last 90 days ·2 sellers, 0 buyers· 10 of 10 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 20, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$5.4M
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Latest filing
Oct 20, 2026
Bizily Scott
4D Molecular Therapeutics, Inc. (FDMT) has 20 SEC Form 4 filings (43 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Oct 20, 2026.
Inside the rolling window, 3 insiders at 4D Molecular Therapeutics, Inc. reported no open-market purchases and 21 open-market sales totaling $5.4M. The most active filer is Chief Legal Officer Bizily Scott with 10 filings. Insiders have net sold $5.3M over the trailing 6 months. The most recent open-market filing is a sale of 1,635 shares by Chief Legal Officer Bizily Scott, dated Oct 16, 2026, worth $21K.
- Industry:Biotechnology
- CEO:David H. Kirn
- Employees:196
- HQ:EmeryVille, CA, US
- IPO:2020-12-11
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Legal Officer | Sale | 1,635 | $21K | Oct 20 | -9.5% | SEC ↗ | |
| See Remarks | Sale | 58,333 | $754K | Oct 7 | -5.9% | SEC ↗ | |
| Chief Legal Officer | Sale | 1,635 | $22K | Sep 22 | -25.4% | SEC ↗ | |
| See Remarks | Sale | 58,333 | $811K | Sep 16 | -13.9% | SEC ↗ | |
| Chief Legal Officer | Sale | 584 | $8K | Sep 3 | -19.4% | SEC ↗ | |
| See Remarks | Sale | 69,076 | $1.1M | Aug 21 | -25.1% | SEC ↗ | |
| Chief Legal Officer | Sale | 1,635 | $20K | Aug 17 | -18.5% | SEC ↗ | |
| Chief Legal Officer | Sale | 1,635 | $20K | Aug 17 | -18.5% | SEC ↗ | |
| See Remarks | Sale | 26,842 | $275K | Aug 5 | — | SEC ↗ | |
| See Remarks | Sale | 12,415 | $125K | Aug 4 | — | SEC ↗ | |
| See Remarks | Sale | 42,608 | $548K | Jul 14 | — | SEC ↗ | |
| See Remarks | Sale | 15,725 | $189K | Jul 14 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 6,566 | $92K | Jul 2 | — | SEC ↗ | |
Bizily ScottFirst in 6 months | Chief Legal Officer | Sale | 9,810 | $118K | Jun 25 | — | SEC ↗ |
| See Remarks | Sale | 114,746 | $1.2M | Jun 23 | — | SEC ↗ | |
Kirn DavidFirst filing | See Remarks | Sale | 1,922 | $19K | Jun 2 | — | SEC ↗ |
Gupta AshooFirst in 3 months | VP, Finance and Controller | Sale | 390 | $3K | Mar 24 | — | SEC ↗ |
Gupta AshooFirst filing | VP, Finance and Controller | Sale | 389 | $3K | Dec 23 | — | SEC ↗ |
| Chief Legal Officer | Sale | 1,635 | $18K | Dec 19 | — | SEC ↗ | |
| Chief Legal Officer | Sale | 1,635 | $17K | Nov 19 | — | SEC ↗ | |
Bizily ScottFirst filing | Chief Legal Officer | Sale | 2,678 | $32K | Oct 27 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does FDMT have?
4D Molecular Therapeutics, Inc. (FDMT) has 20 SEC Form 4 filings (43 transaction rows) in the rolling 365-day window, disclosed by 3 distinct insiders. Most recent filing: Oct 20, 2026.
When was the most recent SEC Form 4 filing for FDMT?
The most recent Form 4 filing for FDMT on Tracefour is dated Oct 20, 2026.
Who is the most active insider at FDMT?
The most active SEC Form 4 filer at FDMT in the rolling window is Chief Legal Officer Bizily Scott, with 10 filings.
What is the net insider flow at FDMT over the last 6 months?
Over the trailing 180 days, insiders at FDMT have net sold $5.3M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at FDMT in the current window?
Inside the rolling window, insiders at FDMT bought $0 and sold $5.4M based on SEC Form 4 filings.
Can I get alerts for FDMT insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at 4D Molecular Therapeutics, Inc. (FDMT). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
4D Molecular Therapeutics, Inc. is in the Healthcare sector.